Targeting cancer's weaknesses (not its strengths)

Therapeutic strategies suggested by the atavistic model

Charles H. Lineweaver, Paul Davies, Mark D. Vincent

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

In the atavistic model of cancer progression, tumor cell dedifferentiation is interpreted as a reversion to phylogenetically earlier capabilities. The more recently evolved capabilities are compromised first during cancer progression. This suggests a therapeutic strategy for targeting cancer: design challenges to cancer that can only be met by the recently evolved capabilities no longer functional in cancer cells. We describe several examples of this target-the-weakness strategy. Our most detailed example involves the immune system. The absence of adaptive immunity in immunosuppressed tumor environments is an irreversible weakness of cancer that can be exploited by creating a challenge that only the presence of adaptive immunity can meet. This leaves tumor cells more vulnerable than healthy tissue to pathogenic attack. Such a target-the-weakness therapeutic strategy has broad applications, and contrasts with current therapies that target the main strength of cancer: cell proliferation.

Original languageEnglish (US)
Pages (from-to)827-835
Number of pages9
JournalBioEssays
Volume36
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Tumors
Cells
Neoplasms
Immune system
Cell proliferation
Therapeutics
Tissue
Adaptive Immunity
Cell Dedifferentiation
Immune System
Cell Proliferation

Keywords

  • Adaptive immunity
  • Cancer therapy
  • Carcinogenesis
  • Evolution of multicellularity

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Targeting cancer's weaknesses (not its strengths) : Therapeutic strategies suggested by the atavistic model. / Lineweaver, Charles H.; Davies, Paul; Vincent, Mark D.

In: BioEssays, Vol. 36, No. 9, 2014, p. 827-835.

Research output: Contribution to journalArticle

@article{1381a2a08a954d41a320415570d80bc9,
title = "Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model",
abstract = "In the atavistic model of cancer progression, tumor cell dedifferentiation is interpreted as a reversion to phylogenetically earlier capabilities. The more recently evolved capabilities are compromised first during cancer progression. This suggests a therapeutic strategy for targeting cancer: design challenges to cancer that can only be met by the recently evolved capabilities no longer functional in cancer cells. We describe several examples of this target-the-weakness strategy. Our most detailed example involves the immune system. The absence of adaptive immunity in immunosuppressed tumor environments is an irreversible weakness of cancer that can be exploited by creating a challenge that only the presence of adaptive immunity can meet. This leaves tumor cells more vulnerable than healthy tissue to pathogenic attack. Such a target-the-weakness therapeutic strategy has broad applications, and contrasts with current therapies that target the main strength of cancer: cell proliferation.",
keywords = "Adaptive immunity, Cancer therapy, Carcinogenesis, Evolution of multicellularity",
author = "Lineweaver, {Charles H.} and Paul Davies and Vincent, {Mark D.}",
year = "2014",
doi = "10.1002/bies.201400070",
language = "English (US)",
volume = "36",
pages = "827--835",
journal = "BioEssays",
issn = "0265-9247",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Targeting cancer's weaknesses (not its strengths)

T2 - Therapeutic strategies suggested by the atavistic model

AU - Lineweaver, Charles H.

AU - Davies, Paul

AU - Vincent, Mark D.

PY - 2014

Y1 - 2014

N2 - In the atavistic model of cancer progression, tumor cell dedifferentiation is interpreted as a reversion to phylogenetically earlier capabilities. The more recently evolved capabilities are compromised first during cancer progression. This suggests a therapeutic strategy for targeting cancer: design challenges to cancer that can only be met by the recently evolved capabilities no longer functional in cancer cells. We describe several examples of this target-the-weakness strategy. Our most detailed example involves the immune system. The absence of adaptive immunity in immunosuppressed tumor environments is an irreversible weakness of cancer that can be exploited by creating a challenge that only the presence of adaptive immunity can meet. This leaves tumor cells more vulnerable than healthy tissue to pathogenic attack. Such a target-the-weakness therapeutic strategy has broad applications, and contrasts with current therapies that target the main strength of cancer: cell proliferation.

AB - In the atavistic model of cancer progression, tumor cell dedifferentiation is interpreted as a reversion to phylogenetically earlier capabilities. The more recently evolved capabilities are compromised first during cancer progression. This suggests a therapeutic strategy for targeting cancer: design challenges to cancer that can only be met by the recently evolved capabilities no longer functional in cancer cells. We describe several examples of this target-the-weakness strategy. Our most detailed example involves the immune system. The absence of adaptive immunity in immunosuppressed tumor environments is an irreversible weakness of cancer that can be exploited by creating a challenge that only the presence of adaptive immunity can meet. This leaves tumor cells more vulnerable than healthy tissue to pathogenic attack. Such a target-the-weakness therapeutic strategy has broad applications, and contrasts with current therapies that target the main strength of cancer: cell proliferation.

KW - Adaptive immunity

KW - Cancer therapy

KW - Carcinogenesis

KW - Evolution of multicellularity

UR - http://www.scopus.com/inward/record.url?scp=84905918016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905918016&partnerID=8YFLogxK

U2 - 10.1002/bies.201400070

DO - 10.1002/bies.201400070

M3 - Article

VL - 36

SP - 827

EP - 835

JO - BioEssays

JF - BioEssays

SN - 0265-9247

IS - 9

ER -